ArticleArchives of Iranian medicine2025
Association of Serum Lipids with 10-Year CVD and All-Cause Mortality in Iranian Adults: A Prospective Cohort Study.
Article in Archives of Iranian medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with abnormal serum lipid levels are at an augmented risk of atherosclerotic cardiovascular diseases (CVDs). The purpose of this study was to evaluate the significance of serum lipid concentrations as determinants for the risk of CVD and all-cause mortality (ACM).
methodsThis prospective cohort study involved individuals who were part of the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study initiated in 2007. A total of 9704 individuals aged 35- 65 years were involved in the current study. The participants were monitored for about a decade to track mortality and its underlying causes. Multivariable Cox proportional hazards models were applied to estimate hazard ratios (HRs) for serum levels of LDL-C, HDL-C, non-HDL-C, and triglycerides (TG), analyzed both as continuous variables and categorized into tertiles. Three models were developed: Model 1 (unadjusted), Model 2 (adjusted for age and sex), and Model 3 (further adjusted for BMI, smoking status, diabetes, hypertension, CVD, job, marital status, education level, and lipid-lowering drugs use). Kaplan-Meier survival analysis compared outcomes across lipid tertiles. Subgroup analyses were also performed to evaluate and control for confounding variables related to serum lipid levels and mortality.
resultsOver a follow-up period of 10 years, there were 429 (4.4%) deaths, including 185 cases due to CVD and 124 cases due to cancer. LDL-C, HDL-C, non-HDL cholesterol, and TG were categorized into three groups based on tertiles. Based on Cox model analysis, after full adjustment, individuals in the second (37.9-45.8 mg/dL) and third (45.8-96.2 mg/dL) tertiles of HDL-C had a significantly lower risk of ACM compared with the lowest tertile (≤37.9 mg/dL) (HR=0.72, 95% CI: 0.57-0.92; and HR=0.81, 95% CI: 0.64-1.03, respectively). Similarly, the risk of cardiovascular mortality was reduced in the second tertile (HR=0.66, 95% CI: 0.46-0.94). No significant associations were found between LDL-C and mortality after adjustment. Kaplan-Meier analyses confirmed significant survival differences across HDL-C (
conclusionAbnormal levels of serum lipids, specifically low HDL-C concentration, are associated with an elevated risk of both non-CVD and CVD mortality. These relationships were widely seen across clinical categories, exhibiting substantially greater patterns in older participants and in persons with hypertension or diabetes. These findings indicate that HDL-C may assist in identifying individuals at increased mortality risk within this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.